key: cord-1007631-eprjumc8
authors: Ohman, J. Westley; Annest, Stephen J.; Azizzadeh, Ali; Burt, Bryan M.; Caputo, Francis J.; Chan, Colin; Donahue, Dean M.; Freischlag, Julie A.; Gelabert, Hugh A.; Humphries, Misty D.; Illig, Karl A.; Lee, Jason T.; Lum, Ying Wei; Meyer, Richard D.; Pearl, Gregory J.; Ransom, Erin F.; Sanders, Richard J.; Teijink, Joep A.W.; Vaccaro, Patrick S.; van Sambeek, Marc R.H. M.; Vemuri, Chandu; Thompson, Robert W.
title: Special Communication: Evaluation and Treatment of Thoracic Outlet Syndrome During the Global Pandemic Due to SARS-CoV-2 and COVID-19
date: 2020-06-01
journal: J Vasc Surg
DOI: 10.1016/j.jvs.2020.05.048
sha: 752998d0bce3a6dc833053ded17c8f5a6ecf0656
doc_id: 1007631
cord_uid: eprjumc8

The global SARS-CoV-2/COVID-19 pandemic has required a reduction in non-emergency treatment for a variety of disorders. This report summarizes conclusions of an international multidisciplinary consensus group assembled to address evaluation and treatment of patients with thoracic outlet syndrome (TOS), a group of conditions characterized by extrinsic compression of the neurovascular structures serving the upper extremity. The following recommendations were developed in relation to the 3 defined types of TOS (neurogenic, venous, and arterial) and 3 phases of pandemic response (preparatory, urgent with limited resources, and emergency with complete diversion of resources): (1) In-person evaluation and treatment for neurogenic TOS (interventional or surgical) is generally postponed during all pandemic phases, with telephone/telemedicine visits and at-home physical therapy exercises recommended when feasible. (2) Venous TOS presenting with acute upper extremity deep vein thrombosis (Paget-Schroetter syndrome) is managed primarily with anticoagulation, with percutaneous interventions for venous TOS (thrombolysis) considered in early phases (I and II) and surgical treatment delayed until pandemic conditions resolve. Catheter-based interventions may also be considered for selected patients with central subclavian vein obstruction and threatened hemodialysis access in all pandemic phases, with definitive surgical treatment postponed. (3) Evaluation and surgical treatment for arterial TOS should be reserved for limb-threatening situations, such as acute upper extremity ischemia or acute digital embolization, in all phases of pandemic response. In late pandemic phases surgery should be restricted to thrombolysis or brachial artery thromboembolectomy, with more definitive treatment delayed until pandemic conditions resolve.

Thoracic outlet syndrome (TOS) refers to a group of conditions in which the neurovascular 2 structures that serve the upper extremity are subject to extrinsic compression as they pass 3 through the base of the neck, underneath the clavicle, over the first rib, and extending to the 4 subcoracoid space. 1 standards of the Society for Vascular Surgery. 2 16 17 In December 2019, clustered cases of a severe atypical pneumonia were first observed in Wuhan, 18 China, which were subsequently attributed to a novel coronavirus designated SARS-CoV-2. 3-5 19 By March 2020, rapid worldwide spread of SARS-CoV-2 infection led the World Health 20

Organization to declare a public health emergency of international concern and a global 21 pandemic. 6 The first case of COVID-19 in the United States was reported on January 20, 2020, 22 followed by evidence for person-to-person transmission and community spread. 7, 8 Travel 23 6 restrictions were implemented in the United States in February 2020 and public health 1 containment and mitigation measures quickly followed. In early March 2020, the Centers for 2 Disease Control and Prevention recommended that hospitals and medical practitioners prepare 3 for a surge in COVID-19 cases that threatened to overwhelm medical resources. Tiered 4 frameworks to guide non-emergency surgery were independently developed by The Centers for 5

Medicare & Medicaid Services, the American College of Surgeons (ACS), the Society for 6 Vascular Surgery (SVS) and the Vascular and Endovascular Surgical Society (VESS). 9-16 On 7

March 13, 2020, the ACS advised members against performing elective scheduled procedures in 8 order to minimize the use of essential personal protective equipment (PPE), intensive care unit 9 (ICU) beds, and ventilators. 11-14 With regard to the management of TOS, the ACS and SVS 10 guidelines designated surgical treatment for neurogenic TOS in tier 1 (postpone), other venous 11 TOS in tier 2a (consider postponing), and symptomatic venous TOS with acute occlusion and 12 marked swelling, arterial TOS with thrombosis, and thrombolysis (arterial and venous) all in tier 13 2b (postpone if possible). 14, 15 Although these recommendations relate to non-emergency 14 operations they do not address the overall evaluation and treatment for TOS, suggesting that 15 more comprehensive guidelines would be of use. 16

Many physicians are uncertain about the most appropriate approaches to be taken in evaluating 18 patients for suspected TOS. There are also variations and nuances in the approaches taken to 19 clinical evaluation and management of TOS and marked differences in the care provided for 20 these conditions in different clinical settings. These concerns have all been magnified as a result 21 of restricted access to specialists and uncertainty about the most appropriate patient care during 22 the SARS-CoV-2/COVID-19 pandemic. Because much of the care for patients with TOS is 23 considered "elective," in most areas physicians have postponed or cancelled in-person office 1 evaluations and follow-up visits, physical therapy, pain management, imaging and other testing, 2 and the conduct of surgical and interventional procedures. Nonetheless, there remain situations in 3 which patient care must be provided, expertise obtained, and (in some cases) interventions and 4 surgical treatment conducted, depending on the specific clinical situation and the local phase of 5 pandemic response at a given time. The purpose of this report is to describe the approaches that a 6 group of TOS specialists has taken for the evaluation and treatment of TOS during the global 7 SARS-CoV-2/COVID-19 pandemic, in an effort to offer more detailed guidelines and 8 recommendations for other physicians and specialists. Transitions between phases are dependent on local-regional COVID-19 case numbers and 9 hospital resources, and decisions to transition from phase III towards a gradual easing of social 10 distancing and travel restrictions are made at the hospital, community and state-wide levels. conditions and governmental regulations will also influence the incidence and prevalence of the 16 disease, along with potential fluctuations in resources. It is also foreseeable that conditions may 17 arise during any easing of restrictions that will require transitions back to higher-level phases of 18 pandemic response. As restrictions are eased and hospitals transition back from phase III towards 19 phase II and phase I conditions, interventional and surgical treatment for patients with TOS may 20 emerge with a relatively high priority based on published scoring systems. 18 This is based on the 21 recognition that patients with these conditions are often substantially disabled but generally 22 young, active, and otherwise healthy, and that the procedures involved are generally associated 1 with minimal morbidity, no intensive care utilization, and short hospital stays. All surgical procedures related to neurogenic TOS should generally be postponed until the 1 resolution of pandemic conditions. During pandemic phase I, treatment may be considered in 2 exceptional cases of neurogenic TOS with severe, unrelenting, pain, neurological dysfunction, 3 and pronounced functional disability, such as those with Disability of the Arm, Shoulder, and 4

Hand (DASH) scores > 90. 2 It is still recommended that surgery be postponed even for patients 5 with more chronic pain and neurological symptoms in the presence of a cervical rib and 6 thenar/hypothenar muscle atrophy (Gilliat-Sumner hand), which is unlikely to change outcomes 7 in the span of several months given the chronic nature of the clinical presentation. As the diagnosis of arterial TOS involves comprehensive evaluation in accord with established 20 criteria, it is recommended that patients with suspected arterial TOS be referred to a specialist 21 with expertise in management of this condition. 1,2 Arterial TOS involves subclavian artery 22 pathology in the presence of a bony abnormality, such as a cervical rib or anomalous first rib, 23 with subclavian artery stenosis and aneurysm formation which may lead to acute 1 thromboembolism and limb-threatening ischemia. It is important to emphasize that positional 2 absence or dampening of the upper extremity arterial pulses during arm elevation, in the 3 presence of normal arterial pulses with the arm at rest and in the absence of thromboembolism or 4 subclavian artery pathology (thrombosis or aneurysm), does not represent arterial TOS. 5

Additionally, recognition of a cervical rib (via plain film x-rays of the chest or cervical spine), 6

should prompt further axial imaging to evaluate the potential for a subclavian artery aneurysm. 7

Prompt diagnosis, intervention and surgical treatment for acute upper extremity ischemia related 8 to arterial TOS is considered necessary given the potential for limb-threatening complications. In 9 such situations, treatment of arterial TOS is directed toward limb salvage and achieving optimal 10 upper extremity function, and is thereby considered "urgent" or "emergent" even under 11 pandemic conditions. Arterial TOS in the absence of acute upper extremity ischemia, such as 12 with digital embolization and subclavian artery aneurysm, has the potential to progress to more 13 severe, limb-threatening, ischemia that may lead to the need for urgent or emergency treatment. 14 Such situations thereby warrant urgent evaluation and appropriate treatment considerations to 15 prevent progression, even if not providing definitive management. 16

In-person routine office evaluations for new patients with suspected arterial TOS without 18 evidence of distal embolic disease are not conducted, but are deferred until the resolution of 19 pandemic conditions; however, it is recommended that initial patient-physician interaction be 20 offered by telephone/telemedicine at the discretion of the TOS specialist, to offer education and 21 help alleviate patient anxiety, with the recognition that definitive clinical diagnosis of arterial 22 TOS requires in-person physical examination and appropriate vascular imaging studies (eg, 23

Duplex ultrasound, CT angiography, MR angiography, or catheter-based arteriography). 2, 19 1 Prescriptions for outpatient oral antiplatelet or anticoagulation treatment (with a NOAC or 2 injectable heparin to avoid the need for laboratory blood testing with warfarin) may be 3 recommended or written by the TOS specialist, based on an adequate telemedicine consultation 4 and a presumptive clinical or radiographic diagnosis of subclavian artery aneurysm. It is also 5 recommended that patients with a presumptive diagnosis of arterial TOS have restrictions placed 6 on elevated arm activity with the affected upper extremity. The SARS-CoV-2/COVID-19 pandemic has placed enormous and unprecedented strain on 2 medical care systems across the globe. With emergency room, hospital, and intensive care 3 utilization rapidly outstripping the available resources, one of the primary goals of physicians 4 and surgeons during this time is to preserve and expand hospital resources ("staff, space, and 5 stuff"). 21-23 The management of TOS varies according to the particular type, but surgical therapy 6 of neurogenic and venous TOS should generally not be offered due to the risks of SARS-CoV- 2 7 infection and transmission, as well as the need to limit exposure of medical personnel and the 8 consumption of hospital resources. Surgical treatment for arterial TOS should also be limited as 9 much as possible, and when necessary for limb salvage, should be largely confined to brachial-10 based interventions. In most cases, more definitive surgical treatment for all forms of TOS is 11 deferred or postponed until the easing of restrictions and resolution of pandemic conditions. 12

Regrettably, it is foreseeable that future infectious disease pandemics will arise that may once 13 again threaten to overwhelm regional and national health care infrastructures, for which we hope 14 these guidelines will be of value as a framework for evaluation and management of patients with 15 TOS. 16 

Reporting 4 standards of the Society for Vascular Surgery for thoracic outlet syndrome

A pneumonia outbreak 7 associated with a new coronavirus of probable bat origin

Clinical features of patients infected 9 with 2019 novel coronavirus in Wuhan, China

Early transmission dynamics in 11

of novel coronavirus-infected pneumonia

World Health Organization. WHO characterizes COVID-19 as a pandemic

Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus 18 in the United States

Illinois COVID-19 Investigation Team. First known person-to-person transmission of severe 21

American College of Surgeons. Guidance for triage of non-emergent surgical procedures

American College of Surgeons. COVID-19 guidelines for triage of thoracic patients

American College of Surgeons. COVID-19 guidelines for triage of vascular surgery patients

Vascular surgery triage by tier class

Vascular and Endovascular Surgery Society. VESS COVID-19 statement

Institute for Health Metrics and Evaluation COVID-19 Health Service 4

Forecasting COVID-19 impact on 5 hospital bed-days, ICU-days, ventilator-days and deaths by US state in the next 4 months

Medically necessary, time-sensitive procedures: scoring system to ethically 9 and efficiently manage resource scarcity and provider risk during the COVID-19 pandemic

Vascular and Endovascular Surgery Society. VESS telemedicine statement

False-negative upper 15 extremity ultrasound in the initial evaluation of patients with suspected subclavian vein 16 thrombosis due to thoracic outlet syndrome (Paget-Schroetter syndrome)

Letter from Seattle: amid COVID-19 pandemic

The authors thank Karen M. Henderson, RN, BSN, for assistance in teleconference organization. 19 

Endovascular interventions potentially applicable to the initial treatment of arterial TOS, 1 including catheter-directed thrombolysis of the axillary or subclavian arteries, are considered 2 appropriate in the setting of limb-threatening ischemia or arterial thromboembolism, in all phases 3 of response to pandemic conditions. For patients with subacute or chronic symptoms attributable 4 to arterial TOS, and for those with asymptomatic (incidentally identified) axillary or subclavian 5 artery aneurysms, such interventions are generally deferred while the patient is treated with 6 antiplatelet and/or anticoagulation medications, until the resolution of pandemic conditions. 7 8 Surgical treatment for acute upper extremity ischemia due to brachial artery thromboembolism is 9 recommended on an emergency basis in all phases of response to pandemic conditions. This is